Vaxxinity, a Phase 2 biotech developing vaccine therapies for chronic diseases using synthetic peptides, announced terms for its IPO on Friday.
The Dallas, TX-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Vaxxinity would command a fully diluted market value of $2.1 billion.
Vaxxinity's vision is to disrupt the existing treatment paradigm for chronic diseases, and believes its synthetic peptide vaccine platform (Vaxxine Platform) has the potential to enable a new class of therapeutics. Its Vaxxine Platform is designed to harness the immune system to convert the body into its own "drug factory," stimulating the production of antibodies with a therapeutic or protective effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer's Disease (AD), Parkinson's Disease, migraine, and hypercholesterolemia. Its most advanced candidate, UB-311, targets toxic forms of aggregated amyloid-b in the brain to fight AD. The company expects to initiate a Phase 2b early AD efficacy trial in 2022. Vaxxinity is also developing a candidate for COVID-19 prevention.
Vaxxinity was founded in 2014 and plans to list on the Nasdaq under the symbol VAXX. BofA Securities, Jefferies, and Evercore ISI are the joint bookrunners on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.